DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass

Osteoporosis International

Volumn 20, Issue 6, 2009, Pages 911-921

  Bonnick, S L ^a   Beck, T J ^b   Cosman, F ^c   Hochberg, M C ^d   Wang, H ^e   De Papp, A E ^e  

^a Clinical Research Center of North Texas   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HELEN HAYES HOSPITAL   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alendronate; BMD; DXA; HSA; Risedronate

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS SOFTWARE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FRACTURE; GEOMETRY; HIP STRUCUTRE ANALYSIS; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MEASUREMENT; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; STRUCTURE ANALYSIS;

ABSORPTIOMETRY, PHOTON; ALENDRONATE; BONE DENSITY; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FEMUR; FRACTURES, BONE; HIP; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT;

EID: 67349245959     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0762-4     Document Type: Article

References (45)

1. TJ Beck 2007 Extending DXA beyond bone mineral density: understanding hip structure analysis Curr Osteoporos Rep 5 49 55
2. RP Heaney 2005 BMD: the problem Osteoporos Int 16 1013 1015
3. TJ Beck CB Ruff KE Warden 1990 Predicting femoral neck strength from bone mineral data A structural approach. Invest Radiol 25 6 18
4. T Beck 2003 Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities Osteoporos Int 14 S81 S88
5. T Yoshikawa CH Turner M Peacock 1994 Geometric structure of the femoral neck measured using dual-energy X-ray absorptiometry J Bone Miner Res 9 1053 1064
6. CJ Rosen MC Hochberg SL Bonnick 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study J Bone Miner Res 20 141 151
7. DM Reid D Hosking D Kendler 2006 Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS-international Clin Drug Investig 26 63 74
8. S Bonnick KG Saag DP Kiel 2006 Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years J Clin Endocrinol Metab 91 2631 2637
9. DM Reid D Hosking D Kendler 2008 A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International Int J Clin Pract 62 575 584
10. RB Martin DB Burr 1984 Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry J Biomech 17 195 201
11. SR Cummings DB Karpf F Harris 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 281 289
12. RD Wasnich PD Miller 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density J Clin Endocrinol Metab 85 231 236
13. MC Hochberg S Greenspan RD Wasnich 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 1586 1592
14. S Sarkar BH Mitlak M Wong 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner. Res 17 1 10
15. J Shih DC Bauer J Orloff 2007 Proportion of fracture risk reduction explained by BMD changes using Freedman analysis depends on choice of predictors Osteoporos Int 13 S38 S39
16. NB Watts C Cooper R Lindsay 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261
17. Z Li MP Meredith MS Hoseyni 2001 A method to assess the proportion of treatment effect explained by a surrogate endpoint Stat Med 20 3175 3188
18. P Chen PD Miller PD Delmas 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis J Bone Miner Res 21 1785 1790
19. JM Buckley K Loo J Motherway 2007 Comparison of quantitative tomography-based measures in predicting vertebral compressive strength Bone 40 767 774
20. RP Crawford CE Cann TM Keaveny 2003 Finite elements models predict in vitro vertebral body compressive strength better than quantitative computed tomography Bone 33 744 750
21. JH Keyak SA Rossi KA Jones 1998 Prediction of femoral fracture load using automated finite element modeling J Biomech 31 125 133
22. W Pistoia BV Van Rietbergen E-M Lochmüller 2002 Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images Bone 30 842 848
23. DL Kopperdahl EF Morgan TM Keaveny 2002 Quantitative computed tomography estimates of the mechanical properties of human vertebral trabecular bone J Orthop Res 20 801 805
24. Kaptoge S, Beck TJ, Reeve J, et al (2008) Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the Study of Osteoporotic Fractures. J Bone Miner Res doi: 10.1359/jbmr.080802
25. F Rivadeneira MC Zillikens CE De Laet 2007 Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study J Bone Miner Res 22 1781 1790
26. Y Duan TJ Beck XF Wang 2003 Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging J Bone Miner Res 18 1766 1774
27. CC Glüer SR Cummings A Pressman 1994 Prediction of hip fractures from pelvic radiographs: the Study of Osteoporotic Fractures. The Study of Osteoporotic Fractures Research Group J Bone Miner Res 9 671 677
28. KL Bell N Loveridge J Power 1999 Structure of the femoral neck in hip fracture: cortical bone loss in the inferoanterior to superoposterior axis J Bone Miner Res 14 111 119
29. P Mayhew S Kaptoge N Loveridge 2004 Discrimination between cases of hip fracture and controls is improved by hip structural analysis compared to areal bone mineral density. An ex vivo study of the femoral neck Bone 34 352 361
30. K Uusi-Rasi TJ Beck LM Semanick 2006 Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial Osteoporos Int 17 575 586
31. K Uusi-Rasi LM Semanick JR Zanchetta 2005 Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women Bone 36 948 958
32. SL Greenspan TJ Beck NM Resnick 2005 Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial J Bone Miner Res 20 1525 1532
33. van Londen GJ, Perera S, Vujevich KT, et al (2008) Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone doi: 10.1016/j.bone.2008.03.027
34. Bone HG, Bolognese MA, Yuen CK, et al (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab doi: 10.1210/jc.2007-2814
35. Beck TJ, Lewiecki EM, Miller PD, et al (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351-359
36. B Ettinger DM Black BH Mitlak 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial JAMA 282 637 645
37. JCH Goh SL Low K Bose 1995 Effect of femoral rotation on bone mineral density measurements with dual energy X-ray absorptiometry Calcif Tissue Int 57 340 343
38. BCC Khoo TJ Beck QH Qiao 2005 In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials Bone 37 112 121
39. P Roschger S Rinnerthaler J Yates 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women Bone 29 185 191
40. L-G Ste-Marie E Sod T Johnson 2004 Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis Calcif Tissue Int 75 469 476
41. 3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women J Clin Endocrinol Metab 88 4199 4205
42. G Boivin S Vedi DW Purdie 2005 Influence of estrogen therapy at conventional and high doses on the degree of mineralization of iliac bone tissue: a quantitative microradiographic analysis in postmenopausal women Bone 36 562 567
43. BM Misof P Roschger F Cosman 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment J Clin Endocrinol Metab 88 1150 1156
44. HG Ahlborg ND Nguyen TV Nguyen 2005 Contribution of hip strength indices to hip fracture risk in elderly men and women J Bone Miner Res 20 1820 1827
45. LJ Melton TJ Beck S Amin 2005 Contributions of bone density and structure to fracture risk assessment in men and women Osteoporos Int 16 460 467